v3.26.3
Earnings (loss) per share - Schedule of Earnings per Share (Detail) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Basic earnings (loss) attributable to Teva’s ordinary shareholders (numerator):        
Net income (loss) attributable to Teva’s ordinary shareholders $ 233 $ 433 $ 26 $ 930
Shares (denominator):        
Weighted average shares outstanding, basic (in shares) 1,166 1,147 1,162 1,144
Basic earnings (loss) attributable to Teva's ordinary shareholders (in dollars per share) $ 0.20 $ 0.38 $ 0.02 $ 0.81
Diluted earnings (loss) attributable to Teva’s ordinary shareholders (numerator):        
Net income (loss) attributable to Teva’s ordinary shareholders $ 233 $ 433 $ 26 $ 930
Shares (denominator):        
Weighted average shares outstanding, basic (in shares) 1,166 1,147 1,162 1,144
Diluted effect of stock options, RSUs and PSUs (in shares) 17 17 18 16
Total dilutive shares outstanding (in shares) 1,183 1,164 1,180 1,160
Diluted earnings (loss) attributable to Teva’s ordinary shareholders (in dollars per share) $ 0.20 $ 0.37 $ 0.02 $ 0.80